Viridian Therapeutics, Inc. (VRDN)
NASDAQ: VRDN · Real-Time Price · USD
23.66
+0.65 (2.82%)
Oct 30, 2025, 4:00 PM EDT - Market closed
Viridian Therapeutics Employees
Viridian Therapeutics had 143 employees as of December 31, 2024. The number of employees increased by 49 or 52.13% compared to the previous year.
Employees
143
Change (1Y)
49
Growth (1Y)
52.13%
Revenue / Employee
$2,133
Profits / Employee
-$1,928,273
Market Cap
1.93B
Employees Chart
Employees History
| Date | Employees | Change | Growth |
|---|---|---|---|
| Dec 31, 2024 | 143 | 49 | 52.13% |
| Dec 31, 2023 | 94 | 8 | 9.30% |
| Dec 31, 2022 | 86 | 36 | 72.00% |
| Dec 31, 2021 | 50 | 23 | 85.19% |
| Dec 31, 2020 | 27 | -19 | -41.30% |
| Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Related Stocks
| Company Name | Employees |
|---|---|
| UnitedHealth Group | 400,000 |
| Johnson & Johnson | 138,100 |
| Thermo Fisher Scientific | 125,000 |
| Abbott Laboratories | 114,000 |
| AstraZeneca | 92,900 |
| Novo Nordisk | 77,349 |
| Novartis AG | 75,883 |
| Merck & Co. | 75,000 |
VRDN News
- 9 days ago - Viridian Therapeutics Announces Pricing of $251 Million Public Offering of Shares of Common Stock - Business Wire
- 9 days ago - Viridian Therapeutics Announces Proposed Underwritten Public Offering - Business Wire
- 10 days ago - Viridian Therapeutics Announces Royalty Financing with DRI Healthcare for up to $300 Million - Business Wire
- 4 weeks ago - Viridian Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - Business Wire
- 4 weeks ago - Viridian Therapeutics: De-Risked Leadership In Thyroid Eye Disease - Seeking Alpha
- 6 weeks ago - Viridian Therapeutics Announces Completion of Enrollment in both REVEAL Clinical Trials and Positive Portfolio Updates - Business Wire
- 3 months ago - These Analysts Revise Their Forecasts On Viridian Therapeutics Following Q2 Results - Benzinga
- 3 months ago - Viridian Therapeutics Highlights Recent Progress and Reports Second Quarter 2025 Financial Results - Business Wire